R.Venkateswari
University of Madras, India
Title: Quercetin enhances the effect of Adriamycin in human hepatocellular carcinoma (HepG2) cell lines
Biography
Biography: R.Venkateswari
Abstract
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide; it is the fifth most common cancer in men and eighth most common in women. HCC results in 2,50,000 to one million deaths globally per annum. Adriamycin is a widely used chemotherapeutic drug used to treat many different forms of cancer, but causes side effects by damaging normal cells leading to cardiotoxicity and nephrotoxicity through the production of free radicals. Quercetin (3,5,7,3´,4´-pentahydroxy flavone) is one of the most abundant bioflavonoids present in edible fruits and vegetables and because of its antioxidant property can reduce the side effects caused by adriamycin. The present study, aims to investigate the in vitro anti-tumorigenic property of quercetin along with Adriamycin in HepG2 cell lines. We examined the cell viability by MTT assay, lipid peroxidation and antioxidant enzymes like catalase, superoxide dismutase, glutathione peroxidase, and glutathione reductase; marker enzymes like ALP, LDH and the gene and protein expression studies of apoptotic genes like Bcl-xl, Bcl 2, Bak, Apaf, Bax, p 53, p21, caspase 3, caspase 9 and PARP in HepG2 cell line. Our study has proved that that quercetin is a very effective growth inhibitor when used alone as well when used in combination with adriamycin in HepG2 cell line. In recent years, research about quercetin has increased both in vitro and in vivo considering it as a promising anti-cancer agent.